Charlie Strange, CHEST 2022: A predictive model to diagnose alpha-1 antitrypsin deficiency

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that remains highly undiagnosed. It is estimated that between 1 to 5% of patients with chronic obstructive pulmonary disease (COPD) have AATD; however is often not diagnosed. We caught up with Prof. Charlie Strange (MUSC, Charleston, SC, USA) to discuss what methods are currently available for the diagnosis of AATD and the development of a novel predictive model for diagnosis.

The abstract ‘A NOVEL PREDICTIVE MODEL USING REAL-WORLD DATA TO IMPROVE DIAGNOSIS OF ALPHA-1 ANTITRYPSIN DEFICIENCY AMONG PATIENTS WITH COPD.’ was presented at CHEST 2022, 16-19 October, 2022.

Questions

1. Why is it important to diagnose alpha-1 antitrypsin (AAT) deficiency among people with COPD? (0:11)
2. What methods are available for the diagnosis of AAT deficiency and what are their limitations? (0:48)
3. Could you tell us a little about your development of a novel predictive model for the diagnosis of AAT deficiency? (1:53)
4. What were the findings of your study? (3:30)

Disclosures: Charlie Strange discloses consulting for CSL Behring, Grifols, Inhibrx, Takeda, and Vertex; receiving grant/ research support from Adverum, Arrowhead, AstraZeneca, Dicerna, Grifols, Takeda, and Vertex; and is a Medical Director at AlphaNet.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.

Filmed in coverage of the CHEST meeting 2022.